Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective Study

Phase 4

Completed

• Conditions: Pancreatic Fistula

• Registration Number: NCT01025414
• Lead Sponsor: Jagiellonian University

Brief Summary

The primary objective of this study is to evaluate the effectives of enteral nutrition in the treatment of pancreatic fistulas. The ratio of pancreatic fistula closure after 30 days is selected as the primary outcome measure with the null hypothesis assuming that enteral nutrition provides better results than parenteral nutrition as far as the closure ratio, time to closure and treatment-related complications are concerned.

Detailed Description

The research into field of the role of enteral nutrition in the treatment of pancreatic fistulas is fully justified by the lower cost and complications' rate of EN compared to PN observed in clinical trials comparing enteral and parnetral route of feeding in pre- and postoperative period. Such authors as Braga, Torosian, Lewis or Sand et al. proved that use of enteral nutrition led to smaller amount of complication (especially infectious) and improved the outcome of surgery. The only method to verify the role of enteral nutrition is the prospective, randomized clinical trial.

STUDY OBJECTIVES 2.1 Primary Objective The primary objective of this study is to evaluate the effectives of enteral nutrition in the treatment of pancreatic fistulas. The ratio of pancreatic fistula closure after 30 days is selected as the primary outcome measure with the null hypothesis assuming that enteral nutrition provides better results than parenteral nutrition as far as the closure ratio, time to closure and treatment-related complications are concerned.

2.2 Secondary Objectives

The secondary objectives are to:

* determine time to fistula closure (defined as time between initiation of treatment and confirmed fistula closure),

* determine rates of fistula and treatment-related complications,

* assess changes in quality of life (QoL),

* determine economic costs of therapy. (for such terms as: fistula closure, time to closure see definition on page 3) For QoL assessment the EORTC QLQ - PAN26 score in Polish version (translation was approved by EORTC) will be used.

Benefits of the study:

1. the implementation of safer and less expensive conservative procedure. Basis: Costs of enteral nutrition are significantly lower than PN and EN is significantly safer than PN especially as far as infectious complications are concerned.

2. the enhancement of indications for enteral nutrition.

The confirmation of the null hypothesis allows recommending enteral nutrition as a method of choice for pancreatic fistula treatment.

Study Timeline

• Study Start: 2006-07
• Primary Completion: 2009-10
• Study Completion: 2009-11
• Status Verified: 2009-12
• Study First Submitted: 2009-12-02
• Study First Submitted QC: 2009-12-02
• Last Update Submitted: 2009-12-02
• Study First Posted: 2009-12-03
• Last Update Posted: 2009-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

• the presence of pancreatic fistula (PF) (verification of serum lipase concentration in drained fluid, findings on imaging modalities: endoscopic retrograde cholangiopancreatography (ERCP), helical computed tomography(hCT), magnetic reissonance imaging (MRI), ultrasonography (USG) or intraoperative surgeon's verification - any or some or all of them)
• good general status (Karnoffsky > 80, Eastern Cooperative Oncology Group (ECOG) scale 0 or 1; see Appendix 2);
• NRS and MUST evaluation - low/ medium risk patients not requiring parenteral nutrition as the essence treatment option,
• no PF's complication requiring special treatment present, such as intraabdominal abscess formation, pleuropneumonia, bleeding, paralytic ileus, etc. Complications will be diagnosed and treated according to generally accepted medical knowledge, standards and procedures.
• age below 80 and over 18;
• in case of neoplastic patients: no confirmed neoplastic dissemination nor distant metastases;
• no severe concomitant disease (heart failure, COPD, CABG, etc.);
• no history of known allergies or drug intolerance;
• informed consent

Exclusion Criteria

• PF diagnosis uncertain;
• poor general status (Karnoffsky <80, ECOG > 1);
• the presence of serious complications; see above
• recent history of severe heart, lung, kidney or liver failure;
• the history of allergies or drug intolerance;
• confirmed neoplastic spread;
• severe malnutrition requiring combined treatment (PN+EN)
• withdrawal of consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The ratio of pancreatic fistula closure after 30 days is selected as the primary outcome measure	30 days

Secondary Outcome Measures

Name	Time	Method
Rates of fistula and treatment-related complications, changes in quality of life	30 days

Trial Locations

Locations (1)

Nutrimed Medical Corporation; 🇵🇱 Krakow, Malopolska, Poland